DDInter118 DDInter1082
Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors.[L45859,A4393] Aripiprazole was given FDA approval on November 15, 2002.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Aripiprazole {u} (Compound) resembles {v} (Compound) Nefazodone
Aripiprazole {u} (Compound) resembles {v} (Compound) Trazodone
Aripiprazole {u} (Compound) binds {v} (Gene) ADRA1B
Aripiprazole {u} (Compound) upregulates {v} (Gene) AARS
Aripiprazole {u} (Compound) palliates {v} (Disease) bipolar disorder
Aripiprazole {u} (Compound) downregulates {v} (Gene) PCNA
Aripiprazole {u} (Compound) causes {v} (Side Effect) Orthostatic hypotension
Aripiprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Aripiprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abarelix
Aripiprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Aripiprazole (Compound) resembles Nefazodone (Compound)
Aripiprazole (Compound) resembles Trazodone (Compound)
Aripiprazole (Compound) binds ADRA1B (Gene)
Aripiprazole (Compound) upregulates AARS (Gene)
Aripiprazole (Compound) palliates bipolar disorder (Disease)
Aripiprazole (Compound) downregulates PCNA (Gene)
Aripiprazole (Compound) causes Orthostatic hypotension (Side Effect)
Aripiprazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Abarelix
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole